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Abstract
Background: Aberrant Hedgehog (Hh) signaling is associated with the development of many cancers including
prostate cancer, gastrointestinal cancer, lung cancer, pancreatic cancer, ovarian cancer, and basal cell carcinoma.
The Hh signaling pathway has been one of the most intensely investigated targets for cancer therapy, and a
number of compounds inhibiting Hh signaling are being tested clinically for treating many cancers. Lung cancer
causes more deaths than the next three most common cancers (colon, breast, and prostate) combined. Cyclopamine
was the first compound found to inhibit Hh signaling and has been invaluable for understanding the function of Hh
signaling in development and cancer. To find novel strategies for combating lung cancer, we decided to characterize
the effect of cyclopamine tartrate (CycT), an improved analogue of cyclopamine, on lung cancer cells and its
mechanism of action.
Methods: The effect of CycT on oxygen consumption and proliferation of non-small-cell lung cancer (NSCLC) cell
lines was quantified by using an Oxygraph system and live cell counting, respectively. Apoptosis was detected by
using Annexin V and Propidium Iodide staining. CycT’s impact on ROS generation, mitochondrial membrane
potential, and mitochondrial morphology in NSCLC cells was monitored by using fluorometry and fluorescent
microscopy. Western blotting and fluorescent microscopy were used to detect the levels and localization of Hh
signaling targets, mitochondrial fission protein Drp1, and heme-related proteins in various NSCLC cells.
Results: Our findings identified a novel function of CycT, as well as another Hh inhibitor SANT1, to disrupt
mitochondrial function and aerobic respiration. Our results showed that CycT, like glutamine depletion, caused a
substantial decrease in oxygen consumption in a number of NSCLC cell lines, suppressed NSCLC cell proliferation,
and induced apoptosis. Further, we found that CycT increased ROS generation, mitochondrial membrane
hyperpolarization, and mitochondrial fragmentation, thereby disrupting mitochondrial function in NSCLC cells.
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Conclusions: Together, our work demonstrates that CycT, and likely other Hh signaling inhibitors, can interrupt NSCLC
cell function by promoting mitochondrial fission and fragmentation, mitochondrial membrane hyperpolarization, and
ROS generation, thereby diminishing mitochondrial respiration, suppressing cell proliferation, and causing apoptosis.
Our work provides novel mechanistic insights into the action of Hh inhibitors in cancer cells.
Keywords: Non-small-cell lung cancer (NSCLC), Hedgehog signaling, Cyclopamine tartrate, SANT1, Oxygen
consumption, Mitochondrial fragmentation, ROS, Apoptosis, Glutamine depletion
Background
Hedgehog (Hh) signaling is a key regulator of develop-
ment and stem cell fate in animals [1]. Dysregulation of
the Hh pathway is responsible for various developmental
malformations, such as holoprosencephaly [2]. Aberrant
activation of the Hh signaling is implicated in a variety
of cancers, such as prostate cancer, gastrointestinal can-
cer, lung cancer, pancreatic cancer, ovarian cancer, and
basal cell carcinoma [3–8]. Therefore, Hh signaling
pathway has become a therapeutic target for treating
many types of cancers. Particularly, a great deal of efforts
have been focused on targeting smoothened (SMO), a G
protein-coupled receptor mediating Hedgehog (Hh) sig-
naling [9]. Many SMO inhibitors have been generated
and tested, and all have shown efficacy as anti-tumor
agents [10]. For example, vismodegib is the first FDA-
approved SMO inhibitor for the treatment of advanced
and metastatic basal cell carcinoma. Currently, vismodegib
and many other SMO inhibitors are being investigated in
clinical trials in a range of advanced cancers [9, 10]. Con-
sequently, understanding the molecular actions of such
inhibitors can be of great value to the improvement of
therapeutic strategies for many types of cancers.
The first identified inhibitor of Hh signaling was cyclo-
pamine, a molecule isolated from corn lilies [11, 12].
Cyclopamine binds to and inhibits SMO. Cyclopamine
has been very valuable for understanding the function of
Hh signaling and has been widely used as an Hh inhibi-
tor in cell and murine models of various tumors [3–5,
13–15]. However, the usefulness of cyclopamine (Cyc) as
a therapeutic drug is hindered by its poor aqueous solu-
bility [16]. To improve the solubility and efficacy of Cyc,
Dr. Garrossian, a contributor of this manuscript, gener-
ated cyclopamine tartrate (CycT) [17]. Indeed, CycT is
water soluble, and its activity in inhibiting Hh signaling
is higher than Cyc. Furthermore, CycT is effective in
causing tumor shrinkage in two mouse models of basal
cell carcinomas [17]. Therefore, we decided to examine
the efficacy of CycT in inhibiting the proliferation and
function of an array of non-small-cell lung cancer
(NSCLC) cell lines.
Previously, using a matched pair of cell lines representing
normal nonmalignant and NSCLC cells developed from
the same patient, we found that oxygen consumption is
intensified in NSCLC cells and tumors [18]. Specifically,
the rates of both glucose and oxygen consumption in
NSCLC HCC4017 cells are elevated, with the elevation of
oxygen consumption greater than that of glucose con-
sumption. Inhibition of mitochondrial respiration inter-
feres strongly with NSCLC cell function, proliferation and
migration [18]. In this paper, we sought ways to suppress
aerobic respiration, which may lead to novel therapeutic
strategies to treat lung cancer and other cancers as well.
Firstly, we found that oxygen consumption is intensified in
an array of NSCLC cell lines. Secondly, we demonstrated
that CycT and another SMO inhibitor SANT1, like glutam-
ine depletion, suppress the rates of oxygen consumption
and the rates of cancer cell proliferation. Further analyses
of various cellular functions showed that CycT, as well as
SANT1, increases ROS generation and mitochondrial
membrane potential in NSCLC cells. Ultimately, these
SMO inhibitors cause mitochondrial fragmentation, lead-
ing to apoptosis. Our studies uncovered a novel mode of
anticancer action of an Hh inhibitor, which may have
broad implications in the development and application of
many Hh inhibitors currently being tested.
Results
Cyclopamine tartrate (CycT), like glutamine depletion,
strongly suppresses oxygen consumption in NSCLC cells
Previously, we showed that the rate of oxygen consump-
tion in NSCLC HCC4017 cells is intensified compared
to the nonmalignant HBEC cells representing normal
lung epithelial cells from the same patient [18], as shown
in Fig. 1a. Additionally, we measured oxygen consump-
tion rates in five other NSCLC cell lines and found that
they were substantially increased in all NSCLC cell lines
(see Fig. 1a). Furthermore, we examined the effect of
glucose depletion, glutamine depletion, and CycT on the
rates of oxygen consumption in these NSCLC cell lines.
We found that glucose depletion generally enhances
oxygen consumption rates, while glutamine depletion di-
minishes the rates (see Fig. 1b-g). Glucose and glutamine
are two critical fuels for cancer cells [19, 20]. When glu-
cose is limiting, the cells use glutamine, and vice versa.
Thus, these results showed that in the absence of glucose,
glutamine supports intensified oxygen consumption in
cancer cells. In the absence of glutamine, even in the
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presence of glucose, oxygen consumption was substantially
reduced (Fig. 1b-g). Notably, CycT diminished the rates of
oxygen consumption in cancer cells largely to the same ex-
tent as glutamine depletion. Likewise, another SMO inhibi-
tor SANT1 [21, 22] diminished oxygen consumption in
NSCLC cells, as expected. These results indicate that CycT
can cause the same effect as glutamine depletion on cancer
cell metabolism and aerobic respiration.
CycT causes apoptosis in NSCLC cells
The data shown above revealed a strong effect of CycT
on aerobic respiration. Thus, we further examined the
Fig. 1 a The rates of oxygen consumption are intensified in various NSCLC cell lines. b-g CycT, like glutamine depletion, strongly diminished
oxygen consumption rates in NSCLC H1299 (b), H1395 (c), Calu-3 (d), A549 (e), HCC4017 (f), and H460 (g) cells. NSCLC cell lines were cultured in
their normal medium or in medium lacking glucose or glutamine, or treated with CycT, as indicated. h SMO inhibitor SANT1, like CycT, can diminish
oxygen consumption in NSCLC cells. H1299 cells were treated with CycT or SANT1. The rates of oxygen consumption were measured. The data shown
were averages of at least three independent measurements. For statistical analysis, the values were compared to that in nontumorigenic HBEC lung
cells (a) or those in normal culture medium (in B-G), by using Welch 2-sample t-test. *, p value < 0.05; **, p value < 0.005
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effect of CycT on NSCLC cell proliferation. We found
that CycT diminishes the proliferation and survival of
NSCLC cells, although the sensitivity of different cell
lines to CycT varies (see Additional file 1: Fig. S1). We
also tested whether CycT causes apoptosis in NSCLC
cells by using Annexin V and propidium iodide (PI)
staining. We found that CycT indeed causes apoptosis in
NSCLC cells, albeit with varying efficacy in different
NSCLC cell lines. For example, after 24 h of treatment
with CycT, H1299 cells were mostly apoptotic, as de-
tected by Annexin V staining (Fig. 2a). PI staining fur-
ther showed that a fraction of these apoptotic H1299
cells were in the late apoptotic stage. A549 cells, as
shown by the proliferation rates in Additional file 1: Fig.
S1, were more resistant to CycT (see Fig. 2b). After 24 h
of treatment, only a fraction of the cells showed signs of
apoptosis, as detected by Annexin V staining. No A549
cells were in late apoptotic stage (see Fig. 2b). Nonethe-
less, our results showed that CycT can cause apoptosis
in NSCLC cells. Notably, another SMO inhibitor
SANT1, like CycT, also exerted similar effects on
NSCLC cells (Fig. 2a and b).
CycT does not exert a considerable effect on heme
metabolism
Heme is a central factor in aerobic respiration and oxi-
dative phosphorylation [23]. Previously, we have shown
that limiting intracellular heme levels strongly dimin-
ishes mitochondrial respiration and NSCLC cell prolifer-
ation and migration [18]. Therefore, we examined
whether CycT impacts heme synthesis and metabolism.
We found that CycT does not significantly affect the rate
of heme synthesis in NSCLC cells (data not shown). Like-
wise, we found that CycT does not significantly affect the
protein levels of the rate-limiting heme synthetic enzyme
ALAS1 and the degradation enzyme HO1 (see Fig. 3a and
b). For a control, we showed that CycT reduces the level
of the Hh signaling target Gli1 (Fig. 3c), as expected. Fur-
thermore, we found that CycT treatment reduced the
levels of phosphorylated p44/42 MAPK. The activation of
p44/42 MAPK signaling pathway has been shown to be
critical for Hh signaling previously [24]. These results
show that CycT does not affect aerobic respiration by
impacting heme metabolism.
CycT increases ROS generation and interferes with
mitochondrial function in NSCLC cells
To further investigate the mode by which CycT causes
NSCLC cell death, we measured ROS generation in
CycT-treated and untreated NSCLC cells. We found that
CycT causes a substantial increase in ROS generation in
NSCLC cells, including H1299 (Fig. 4a), A549 (Fig. 4b),
and H460 (Fig. 4c) cells. In addition, we found that an-
other SMO inhibitor SANT1 increased ROS generation
in NSCLC cells (Fig. 4d). Because of the dominant role
of mitochondria in oxygen metabolism, mitochondria
are mainly responsible for the generation of cellular
ROS. Therefore, we also examined the effect of CycT on
mitochondrial function. First, we measured and compared
mitochondrial membrane potential in CycT-treated and
CycT-untreated cells. We found that CycT increases mito-
chondrial membrane potential substantially in NSCLC
cells (Fig. 5a, b and c). This effect of CycT appeared to be
stronger in H1299 (Fig. 5a) and H460 (Fig. 5c) cells than
in A549 cells (Fig. 5b). Likewise, another SMO inhibitor
SANT1 increased mitochondrial membrane potential in
NSCLC cells (Fig. 5d).
CycT causes mitochondrial fragmentation in NSCLC cells
Mitochondrial morphology is closely linked to mitochon-
drial function [25]. Changes in mitochondrial morphology
regulate many mitochondrial functions, such as the re-
spiratory activity of the electron transport chain and apop-
tosis [26]. We therefore examined the effect of CycT on
Fig. 2 CycT and SANT1 induce apoptosis in H1299 (a) and A549 (b)
NSCLC cell lines. The NSCLC cells were treated with CycT or SANT1
for 24 h. Then cells were subjected to apoptosis assay by using
Annexin V-FITC and Propidium Iodide (PI) staining. The images of
cells were captured with bright field microscopy (BF) or with fluorescent
microscopy with a FITC or rhodamine (for PI) filter
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mitochondrial morphology in NSCLC cells by using Mito-
Tracker Red. Fig. 6 shows that CycT treatment caused
mitochondrial fragmentation in NSCLC cells, H1299
(Fig. 6a), A549 (Fig. 6b), and H460 (Fig. 6c) cells. SANT1
exerted similar effects on the NSCLC cells (not shown).
Because Drp1 is the main protein promoting mitochondrial
fission and fragmentation [27], we also examined the effect
of CycT on Drp1 distribution. Additional file 2: Fig. S2
shows that in CycT-treated NSCLC H1299 (Additional file
2: Fig. S2A) and A549 (Additional file 2: Fig. S2B) cells,
Drp1 were indeed selectively localized to various mito-
chondrial fission sites: The localization pattern of Drp1
Fig. 3 The effect of CycT treatment on the levels of ALAS1 (a), HO1 (b), Gli1 (c), and phospho-p44/p42 MAPK (d). The NSCLC A549 cells were cultured
and treated with CycT for 24 h [lane 2 in (a) and (b)] or without CycT [lane 1 in (a) and (b)]. In (c) and (d), cells were treated without (lane 1) or with
CycT for 1 (lane 2), 3 (lane 3), 6 (lane 4), 12 (lane 5), and 24 (lane 6) hours as indicated. Protein extracts were prepared and the levels of the proteins
were detected by Western blotting. The protein level of vinculin was used for normalization. For statistical analysis, the levels in treated
cells were compared to the levels in untreated cells, by using Welch 2-sample t-test. *, p value < 0.05
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Fig. 4 CycT treatment increases ROS production in NSCLC H1299 (a), A549 (b), and H460 (c) cells. d SANT1 treatment also increases ROS
production in NSCLC H1299 cells. NSCLC cells were treated with CycT or SANT1 for the indicated time periods. Then cells were incubated
with 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) for 30 min. Fluorescence intensity was measured and normalized according to cell density.
For statistical analysis, the levels in CycT-treated cells were compared to the levels in untreated cells, by using Welch 2-sample t-test. *, p value < 0.05;
**, p value < 0.005
Fig. 5 The effect of CycT treatment on mitochondrial membrane potential in NSCLC H1299 (a), A549 (b), and H460 (c) cells. d SANT1 treatment
also increases mitochondrial membrane potential in NSCLC H1299 cells. NSCLC cells were treated with CycT or SANT1 for the indicated time
periods. Then mitochondrial membrane potential in these cells was measured by using JC-1 staining. Mitochondrial membrane potential was
expressed as the ratio of aggregates/monomer, which was calculated by dividing red fluorescence intensity with green fluorescence intensity. For
statistical analysis, the levels in CycT-treated cells were compared to the levels in untreated cells, by using Welch 2-sample t-test. *, p value < 0.05;
**, p value < 0.005
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completely coincided with the MitoTracker Red staining
pattern. These results demonstrated that CycT can induce
Drp1 to promote mitochondrial fission and fragmentation.
Discussion
Targeting Hh signaling is an important strategy that is
being developed to treat a variety of metastatic and ad-
vanced cancers [9, 28]. Vismodegib, a SMO antagonist,
was the first Hh inhibitor to receive approval from the
USA FDA in January 2012 for the treatment of locally
advanced or metastatic basal cell carcinoma (BCC) [29].
Currently, NIH lists 91 ongoing or completed clinical
trials testing Hh inhibitors against a variety of cancers
(https://clinicaltrials.gov/ct2/results?term=HEDGEHOG).
Therefore, a comprehensive understanding of the modes
of Hh inhibitor action can benefit the treatment of a wide
range of cancers. Here, by using the well-studied Hh in-
hibitor cyclopamine tartrate, we identified a new activity
of this drug against aerobic respiration and mitochondrial
function in NSCLC cancer cells.
First, we found that oxygen consumption is intensified
in an array of NSCLC cell lines and that glutamine has a
prominent role in promoting oxygen consumption, be-
cause glucose depletion in the presence of glutamine en-
hanced oxygen consumption while glutamine depletion
in the presence of glucose diminished oxygen consump-
tion substantially (Fig. 1). This is entirely consistent with
previous studies showing glutamine as the dominant re-
spiratory substrate in tumor cells [30, 31]. Remarkably, we
found that CycT exerted largely the same effect on oxygen
consumption as glutamine depletion (see Fig. 1b-g). Glu-
tamine provides a crucial source of cellular energy and
building blocks for cancer cells, and targeting glutamine
uptake and metabolism has become an important ap-
proach in treating drug-resistant cancers [32, 33]. Our
finding linking both CycT treatment and glutamine deple-
tion with diminished aerobic respiration provides a new
way to control cancer cell bioenergetics. Although differ-
ent NSCLC cell lines exhibited varying rates of oxygen
consumption (Figs. 1b-g), CycT, like glutamine depletion,
strongly diminished oxygen consumption in all cell lines,
suggesting that CycT can be an effective inhibitor of cellu-
lar energy production in all these lines. The same effect of
glutamine depletion and CycT treatment suggests that Hh
inhibitors may be used in substitution of drugs targeting
glutamine metabolism in cancer therapy.
Second, we showed that CycT strongly suppressed
NSCLC cell proliferation (Additional file 1: Fig. S1) and
induced apoptosis (Fig. 2a and b). Notably, apoptosis of
NSCLC cells was preceded by increased ROS generation
(Fig. 4a and b) and increased mitochondrial membrane
potential (Fig. 5a and b). At first sight, increased mito-
chondrial membrane potential accompanying apoptosis
may seem paradoxical. However, hyperpolarization of
mitochondrial membrane potential induced by various
stress factors have been observed in a wide array of cells
ranging from neuronal to blood cells [34]. For example,
both glucose and oxygen deprivation induces mitochon-
drial membrane potential hyperpolarization [35]. Hyper-
polarization of mitochondrial membrane potential will
lead to excessive ROS production [34, 36]. The connec-
tion between the ΔΨm and ROS is exponential when
ΔΨm exceeds 140 mV [37]. Ultimately, increased ROS
generation will lead to apoptosis [38, 39], as indicated in
Figs. 4 and 5.
Third, we found that CycT strongly induced mitochon-
drial fission and fragmentation (Fig. 6). As expected,
CycT-induced mitochondrial fragmentation accompan-
ied the recruitment of Drp1 to the mitochondrial outer
membrane and fission sites (see Additional file 2: Fig.
S2), consistent with previous models of mitochondrial
fission [27]. Mitochondrial fragmentation is often associ-
ated with apoptosis, although it can occur in a variety of
conditions independently of apoptosis [25, 40]. Here our
results suggest that CycT-induced apoptosis in NSCLC
cells is associated with mitochondrial fragmentation.
Interestingly, while CycT caused strong mitochondrial
fragmentation in both A549 and H1299 cells, apoptosis
was much less prominent in A549 cells (Fig. 2),
Fig. 6 CycT treatment causes mitochondrial fragmentation in NSCLC
H1299 (a), A549 (b), and H460 (c) cells. NSCLC cells were treated with
CycT for 24 h, and then stained with MitoTracker Red. Fluorescent
images were acquired and shown here. The scale bar indicates 10 μm
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suggesting differential sensitivity of NSCLC cells to
mitochondrial fragmentation and CycT.
In sum, our results provide novel insights into the po-
tential mechanisms of action of Hh signaling pathway
inhibitors. Previous studies have shown that Gli tran-
scriptional factors are the key mediators of Hh signaling
[1, 2]. Furthermore, genome-wide analyses using gene
expression profiling and chromatin immunoprecipitation
have identified many Gli target genes [41–43]. A careful
examination of these target genes showed that there are
30 genes encoding for mitochondrial functions, such as
MRPL23, GLUL, SLC25A13, PRDX6, and ATP6V1E1
[41]. These targets also include NDUFS8, a subunit of
mitochondrial NADH:ubiquinone oxidoreductase, or
Complex I; Cyb5b, a cytochrome b5 outer mitochondrial
membrane isoform; 1810063B05Rik, cytochrome c oxi-
dase assembly factor 6; and catalase. Although the identifi-
cation of such a relatively small number of mitochondrial
targets does not allow the inference of a global effect of
Hh signaling or Hh inhibitors on mitochondria, it does
lend support to our new finding that the Hh inhibitor
CycT impacts mitochondrial morphology and function,
thereby modulating mitochondrial respiration and apop-
tosis. Further studies comparing SMO inhibitors, such as
CycT, and Gli inhibitors may provide additional insights
into which proteins in the Hh signaling pathway play a
dominant role in mitochondrial morphology and function.
Conclusion
The major findings of our study are: a) CycT, like glutam-
ine depletion, causes a substantial decrease in oxygen con-
sumption in a number of NSCLC cell lines; b) CycT
suppresses proliferation and induces apoptosis in NSCLC
cells; c) CycT and evidently other Hh inhibitors promote
mitochondrial fission and fragmentation, mitochondrial
membrane hyperpolarization, and ROS generation; and d)
Hh signaling inhibitors can act on mitochondria and cause
broad and dramatic changes in mitochondrial morph-
ology, respiration and function. These new findings can
shed light on the mechanisms underlying various cancers
associated with aberrant Hh signaling and can provide
novel insights into how to optimize anti-Hh signaling
strategy for treating cancer.
Methods
Lung cell lines, antibodies and reagents
HBEC30KT and HCC4017 cell lines representing normal
and NSCLC cells [44, 45] were provided by Dr. John
Minna’s lab (UTSW) as a gift. They were developed from
the same patient and were maintained in ACL4 supple-
mented with 2 % FBS under 5 % CO2 at 37 °C [45]. All
other NSCLC cell lines, H1395, H1299, Calu-3, A549
and H460 were purchased from ATCC, and were main-
tained according to ATCC procedures. All tissue culture
media, including those lacking glucose or glutamine,
were purchased from Invitrogen Life Technologies.
HBEC30KT, HCC4017, H1299 and A549, were authenti-
cated by using the services provided by Genetica DNA
Laboratories, and they were found to be 100 % match.
Other NSCLC cell lines were used for measurements
immediately following the purchase. Cyclopamine tar-
trate (CycT) was provided by Logan Natural Products
(Plano, Texas). SANT1 was purchased from Santa Cruz
Biotechnology. For measuring the effect of CycT or
SANT1 on lung cell proliferation, cells were seeded in
48-well plate at a density of 104 cells/well. After cultur-
ing for 24 h, cells were treated with the indicated con-
centrations for 24 h or the indicated time points. At the
indicated times, the number of live cells was counted by
using trypan blue staining and a hemocytometer. Poly-
clonal anti-ALAS1, anti-HO1, anti-Gli1 and anti-Drp1
were purchased from Santa Cruz Biotechnology. Mono-
clonal anti-vinculin antibody was purchased from
Sigma-Aldrich. Polyclonal anti-phospho-p44/42 MAPK
antibody was purchased from Cell Signaling Technology.
Measurement of oxygen consumption rates
NSCLC cells (∼70 % confluence) were maintained in
medium with 25 μM CycT or 50 μM SANT1, or in
medium lacking glucose or glutamine for 24 h. Then
oxygen consumption was measured, as described previ-
ously [46]. Briefly, cells with about 80 % confluence were
trypsinized and resuspended in fresh, air-saturated
medium. For each measurement, 106 cells (in 350 μl)
were introduced in the chamber of an Oxygraph system
(Hansatech Instruments), with a Clark-type electrode
placed at the bottom of the respiratory chamber. During
measurements, the chamber was thermostated at 37 °C
by a circulating water bath. An electromagnetic stirrer
bar was used to mix the contents of the chamber. Each
measurement was replicated at least three times. Stand-
ard deviations were calculated, and p values were calcu-
lated by using Welch 2-sample t-test (R program).
Measurement of ROS generation and mitochondrial
membrane potential
The intracellular ROS levels were measured by using
2,7-dichlorodihydrofluorescein diacetate (DCFH-DA)
(Cayman Chemical), which is oxidized into highly fluor-
escent 2,7- dichlorofluorescein in the presence of intra-
cellular ROS. Cells were seeded in 96-well plates with
black walls and clear bottoms at a density of 10,000 cells
per well. Cells were treated with 25 μM CycT or 50 μM
SANT1 for the indicated times. Cells were then incu-
bated for 30 min with 10 μM DCFH-DA dissolved in
fresh media. Cells were then rinsed twice with PBS, and
each well was filled with 100 μl PBS. Fluorescence was
detected by using a fluorescent plate reader (Bio Tek,
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Synergy Mx microplate reader) with the excitation and
emission wavelengths at 490 and 535 nm, respectively.
Changes in the mitochondrial membrane potential
(ΔΨm) were measured quantitatively by staining with
the cationic dye JC-1(Molecular probes), which accumu-
lates in the mitochondria, showing green fluorescence at
lower membrane potential and forming J-aggregates with
red fluorescence at higher membrane potential. Cells
were seeded in 96 well black wall and clear bottom
plates at a density of 10,000 cells per well. Cells were
treated with 25 μM CycT or 50 μM SANT1 for the indi-
cated times. Cells were then incubated with 200 μl of
fresh medium containing 2 μg/μl of JC-1 dye for 30 min
in the dark. The cells were washed twice with PBS, and
the plates were immediately read with a fluorescent plate
reader (Bio Tek, Synergy Mx microplate reader) with
excitation and emission wavelengths set at 540 and
595 nm, respectively, for red fluorescence; and 485 and
535 nm, respectively, for green fluorescence.
Preparation of protein extracts and Western blotting
NSCLC cells were treated, collected, and lysed by using
the RIPA buffer (Cell Signaling Technology) containing
the protease inhibitor cocktail. Protein concentrations
were determined by using the BCA assay kit (Thermo
Scientific). 50 μg of proteins from each treatment condi-
tion were electrophoresed on 9 % SDS–Polyacrylamide
gels, and then transferred onto the Immuno-Blot PVDF
Membrane (Bio-Rad). The membranes were probed with
polyclonal antibodies, followed by detection with a
chemiluminescence Western blotting kit (Roche Diag-
nostics). The signals were detected by using a Care-
stream image station 4000MM Pro, and quantitation
was performed by using the Carestream molecular im-
aging software version 5.0.5.30 (Carestream Health,
Inc.). Antibodies used were purchased from Santa Cruz
Biotechnology and Sigma-Aldrich.
Mitochondria imaging and indirect immunofluorescence
staining
Mitochondria were visualized by using Mito Tracker
Red CMXRos (Molecular probes), which passively dif-
fuses across the plasma membrane and accumulates in
active mitochondria. Cells were grown on chamber
slides and treated with CycT for 24 h. Cells were then
stained with 200 nM of CMXRos in complete growth
medium for 30 min at 37 °C, washed with prewarmed
PBS three times, and fixed with 4 % formaldehyde in
PBS for 10 min. After washing twice with PBS the slides
were covered, and fluorescent images were captured
with a multi-channel Zeiss Axio Observer Z1 fluorescent
microscope with a Zeiss 40X Oil immersion lens and
with a high speed AxioCam MRm Rev3 monochrome
camera.
Indirect immunofluorescence staining with Drp1 anti-
bodies (purchased from Santa Cruz Biotechnology) was
performed by following the procedures provided by the
antibody manufacturer. FITC and DAPI fluorescent im-
ages were captured by using a multi-channel Zeiss Axio
Observer Z1 fluorescent microscope. Apoptosis was de-
tected by using the ApoAlert Annexin V-FITC Apoptosis
Kit (Clontech). Cells were seeded in a 96-well black wall
clear bottom plate at the density of 10,000 cells per well.
After one day, cells were treated with 25 μM CycT or
SANT1 in fresh medium. Twenty four hours post treat-
ment, apoptosis assay was performed according to manu-
facturer’s protocol. Fluorescent images were captured
using a multi-channel Zeiss Axio Observer Z1 fluorescent
microscope with a Zeiss 20X lens and with a high speed
AxioCam MRm Rev3 monochrome camera.
Ethics approval and consent to participate
There was not any ethics approval or consent required
for the use of human derived cell lines in this study.
Additional files
Additional file 1: Figure S1. The effect of CycT treatment on NSCLC
cancer cell proliferation. %live cells was calculated by dividing the
number of treated cells with the number of untreated cells (seeded with
the same number of cells). It shows the relative proliferative rates of
treated cells (10 or 25 μM) vs. untreated cells (None). For statistical
analysis, the values for treated cells were compared to the values for
untreated cells, by using Welch 2-sample t-test. *, p value < 0.05; **, p
value < 0.005. (JPG 270 kb)
Additional file 2: Figure S2. Drp1 localizes to the mitochondrial fission
sites in CycT-treated NSCLC H1299 (A) and A549 (B) cells. NSCLC cells
were treated with CycT for 24 h. Cells were incubated with anti-Drp1
antibodies, and then with FITC-conjugated goat anti-rabbit secondary
antibody, MitoTracker, as well as DAPI. FITC, MitoTracker and DAPI fluores-
cent images were captured and are shown here. The scale bar indicates
10 μm. (TIF 15003 kb)
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